Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration

Phase 2 Active not recruiting 120 enrolled University Hospital, Antwerp AZ Sint-Jan AV · collab Hasselt University · collab National MS Center Melsbroek · collab Noorderhart Pelt · collab University Hospital, Ghent · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

This clinical trial aims to demonstrate that metformin can prevent clinical disability in patients with progressive MS by stopping or slowing down neurodegeneration by enhancing endogenous remyelination. Patients will continue their DMT treatment: metformin or placebo will be used as add-on study treatment.

Timeline

Start: 2023-11-23
Primary completion: 2027-02-28
Completion: 2027-02-28

Publications

Background De Keersmaecker AV, Van Doninck E, Popescu V, Willem L, Cambron M, Laureys G, D' Haeseleer M, Bjerke M, Roelant E, Lemmerling M, D'hooghe MB, Derdelinckx J, Reynders T, Willekens B. A metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration (MACSiMiSE-BRAIN): study protocol for a multi-center randomized placebo controlled clinical trial. Front Immunol. 2024 Feb 21;15:1362629. doi: 10.3389/fimmu.2024.1362629. eCollection 2024.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Metformin	Small molecule	850 mg	Oral

Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration

Summary

Timeline

Publications

Drugs

Indications